Inhaled Hypertonic Saline Use in the Emergency Department to Treat Acute Viral Bronchiolitis

• Status: Terminated
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Acute viral bronchiolitis is an extremely common childhood disease, responsible for approximately 17% of childhood admissions to hospital per year, with an annually cost that reaches U$ 500 million.

Despite being a well known disease among pediatricians, there are few, if any, effective treatment options apart from oxygen supplementation and adequate hydration.

The purpose of this study is to determine wether nebulized hypertonic saline (3%) is more effective than normal saline (0,9%) when used in repeated doses during the first 24 hours of in-hospital treatment.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Sao Paulo

Criteria

Inclusion Criteria:

• Age < 12 months

• Clinical diagnosis of bronchiolitis (viral respiratory disease and wheezing)

• First episode of wheezing in life

• Moderate respiratory distress, defined as 2 of the following: Sat <93%, respiratory rate >60 and/or RDAI score >4

Exclusion Criteria:

• Previous episodes of wheezing in history

• Use of bronchodilators, corticosteroids or antibiotics in the 24 hours prior to admission or at any time during treatment.

• Other clinical conditions such as: prematurity, bronchopulmonary dysplasia, cystic fibrosis, cardiac disease or immunodeficiencies.

• detection of alveolar infiltrates suggestive of pneumonia in radiologic examination

• respiratory impairment requiring mechanical ventilation on arrival to hospital.